文摘
There are higher rates of anticholinergic AEs like dry mouth and constipation and treatment discontinuation in antimuscarinics versus placebo in the elderly. There are higher rates of non-anticholinergic AEs, such as dyspepsia, dizziness, headache, and urinary tract infections in antimuscarinics versus placebo in the elderly. In head-to-head trials, there are higher rates of AEs in fesoterodine compared to tolterodine extended-release in the elderly. Due to the restrictive inclusion and exclusion criteria, these results should be further confirmed using pharmacoepidemiological techniques.